Paper Details

  1. Home
  2. Paper Details

Clinical benefit of systemic therapies for recurrent ovarian cancer-ESMO-MCBS scores.

Author: BroekmanK E, JalvingM, ReynersA K L, SessaC, van KruchtenM, van TinterenH

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

This study aimed to assess the clinical benefit of treatments for platinum-sensitive recurrent ovarian cancer according to the European Society of Medical Oncology (ESMO)-Magnitude of Clinical Benefit Scale (MCBS). Licensed systemic treatment options for platinum-sensitive recurrent ovarian cancer are platinum-based chemotherapy and maintenance treatment with bevacizumab and poly (ADP-ribose) polymerase inhibitors. For platinum-resistant disease, several non-platinum options are available.
Paper Details　
Original Abstract of the Article :
Licensed systemic treatment options for platinum-sensitive recurrent ovarian cancer are platinum-based chemotherapy and maintenance treatment with bevacizumab and poly (ADP-ribose) polymerase inhibitors. For platinum-resistant disease, several non-platinum options are available. We aimed to assess t...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8358417/

データ提供：米国国立医学図書館（NLM）

Assessing the Clinical Benefit of Therapies for Recurrent Ovarian Cancer

This research evaluates the clinical benefit of various systemic therapies for recurrent ovarian cancer, using the European Society of Medical Oncology (ESMO)-Magnitude of Clinical Benefit Scale (MCBS). Ovarian cancer is a complex and often challenging disease, and the study focuses on assessing the effectiveness of different treatment options, including platinum-based chemotherapy, bevacizumab, poly (ADP-ribose) polymerase inhibitors, and non-platinum therapies for platinum-resistant disease. The study aimed to provide a comprehensive overview of the clinical benefit of these treatments, based on the MCBS scoring system.

A Comprehensive Evaluation of Treatment Options

The study provides a valuable framework for evaluating the clinical benefit of different therapies for recurrent ovarian cancer, using the MCBS scoring system. The research offers a comprehensive overview of the effectiveness of various treatment options, enabling healthcare providers to make informed decisions about treatment strategies.

Navigating Treatment Decisions in Ovarian Cancer

The study highlights the importance of considering the clinical benefit of treatment options when managing recurrent ovarian cancer. The research underscores the need for a nuanced understanding of the effectiveness of various therapies and for personalized decision-making based on the individual patient's needs and circumstances.

Dr.Camel's Conclusion

This research, like a desert navigator using a compass to guide their journey, provides a comprehensive assessment of the clinical benefit of various therapies for recurrent ovarian cancer. The study offers valuable insights for navigating treatment decisions and maximizing patient outcomes in this complex and challenging disease.

Date :
  1. Date Completed 2021-10-29
  2. Date Revised 2022-05-31
Further Info :

Pubmed ID

34371383

DOI: Digital Object Identifier

PMC8358417

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.